An observational study in Sudden Cardiac Death, Exosome Multiomics and Clinical Prognosis, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Death, Sudden, Cardiac with a site in China — 9 open to participants now, 10 under way, none of them phase 3. Death, Sudden, Cardiac · China.
Among the 19 studies in Death, Sudden, Cardiac with a site in China, this one is the 14th largest by planned enrollment of the 15 observational ones that give a count, is one of 3 that started in 2021, is one of 15 observational ones, and was the 13th registered.
364 studies on the registry are indexed under Death, Sudden, Cardiac; 84 are open to participants now.
Browse Death, Sudden, Cardiac studies →9 of the 19 studies in Death, Sudden, Cardiac with a site in China are open now. Recruiting first, the newest first:
Beijing Anzhen Hospital · Sites in China
Ages 18–80
Chensheng Pan · Sites in China
Ages 18+
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 16–90 · Healthy volunteers
Shandong Provincial Hospital · Sites in China
Ages 18+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 63 Death, Sudden, Cardiac studies recruiting now, 42 (67%) set no upper age limit and 11 (17%) stop at 75 or younger; 22 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2021.
This study's planned enrollment of 300 is below the median of 450 across 203 observational studies indexed under Death, Sudden, Cardiac.
Median enrollment 342 across the 4 interventional studies, 1,491 across the 15 observational. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 19 have an industry lead sponsor. The 10 most frequent:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School is the lead sponsor of 251 studies on the registry; 148 are open to participants now.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School has 1 study filed under Death, Sudden, Cardiac — fewer than ten, so there is no comparison to draw.
2 of the studies in Death, Sudden, Cardiac with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06856993The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolEarly Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death | 2026-12-31 |
| NCT07476456China National Center for Cardiovascular DiseasesSkeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Death, Sudden, Cardiac with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Acute coronary syndrome (ACS) is one of the main causes of death. Worldwide, tens of millions of patients are hospitalized for coronary heart disease and ACS every year. ACS may show acute myocardial infarction, unstable angina pectoris, and even induce early arrhythmia, leading to sudden death. Sudden cardiac death (SCD) has a strong correlation with ACS. Data from clinical and autopsy studies and death certificates show that 62-85% of patients with out of hospital SCD have a history of ACS, 10% have other cardiac structural abnormalities, and 5% have no cardiac structural abnormalities. An SCD surveillance study from Ireland concluded that most cases occurred in families, and the successful recovery of SCD was mainly related to ventricular fibrillation with arrhythmia. At present, there are few reports on the clinical and prognosis of ACS in China, and there is no guideline or consensus on the prevention and treatment of ACS patients. Known domestic research results show that the proportion of male, overweight / obese, smokers in young ACS patients is higher than that in the elderly group, while the proportion of patients with hypertension, diabetes and cerebrovascular diseases is less than that of the elderly group. The levels of TC, TG, LDL-C and UA and the proportion of low HDL-C in young ACS patients were higher than those in elderly patients; The diagnosis of STEMI was the highest in the young ACS group, while the diagnosis of unstable angina pectoris was the most common in the elderly ACS group. The clinical manifestations of ACS vary greatly. 3% \~ 5% of patients who exclude ACS only through myocardial markers, clinical blood transfusion and ECG still have myocardial infarction (MI). For the emergency department, early prediction of the risk of SCD in ACS patients and timely and accurate screening of high-risk patients are very important.
Patients with sudden death
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standardized medical care for cardiac arrest includes early cardiopulmonary resuscitation (CPR), defibrillation, advanced cardiac life support (ACLS), post-resuscitation care, and continuous monitoring of the patient's vital functions.
Presence (or not of exosome-associated metabolites, microRNAs, and proteins
This outcome measure evaluates the presence (or not) of specific exosome-associated biomolecules, including metabolites (pyruvate, spermidine, glycine, glucose, L-phenylalanine), microRNAs (microRNA-208b-3p, microRNA-143-3p), and proteins (PSMB10, A1BG).
Time frame: 2 years
Started Dec 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.
Of 70 non-industry observational studies under Death, Sudden, Cardiac, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 42. This study's planned 60 months is below that.
Counting every sponsor, half of 86 studies reached it within 63 months; a quarter within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School →